Progyny is a New York City–based fertility benefits company led by CEO David Schlanger. The company provides fertility solutions for employers, offering comprehensive treatment plans grounded in medical science and technology. Its services aim to improve outcomes, shorten time to pregnancy and reduce total costs related to fertility. Progyny has operations in San Francisco, CA. The company recently raised additional capital, which will support growth of its customer base and expansion of its national network of fertility specialists. Management also plans to use the financing to build out infrastructure and systems to support that growth. Progyny is a New York City–based digital healthcare company that combines data, science and technology to provide proactive fertility solutions. Its core offering is a fertility benefits solution for large, self‑insured employers and consumers, centered on its SMART™ Cycle plan design. SMART™ Cycle comprises research and clinical solutions and leverages proprietary (Eeva) technology to improve outcomes, shorten time to pregnancy and reduce total fertility‑related costs. The company plans to use the Series B proceeds to accelerate growth of its proprietary technology and fertility benefits solution, and to launch new products and services including a new app. Led by CEO Gina Bartasi and CTO George Nassef, Progyny also operates in San Francisco and Menlo Park, CA. The article reports a $14.7m Series B financing. Progyny is a combined entity of Auxogyn, Inc. and Fertility Authority, LLC that operates an online marketplace for families seeking fertility solutions. Its digital platform gives patients access to doctors, price transparency, financing, and clinical expertise alongside proprietary clinical solutions. Patients are guided through the fertility health journey and receive expert information on elective egg freezing, IVF treatment options, and the Eeva™ Test. The Eeva™ Test is described as an FDA‑cleared, non‑invasive prognostic test that uses time‑lapse imaging and statistical modeling to assess early embryo development with minimal disturbance. The company said the newly secured capital will enable it to expand operations. Progyny is led by CEO Gina Bartasi and president/COO Darrin Uecker and has operations in Menlo Park, California. Auxogyn is a Menlo Park, California company advancing women's reproductive health. Its core product is the Early Embryo Viability Assessment (Eeva), a non-invasive test that provides objective information on embryo viability during in vitro fertilization (IVF). The company raised $18M in a Series B financing to support regulatory clearance and the commercial launch of Eeva. The round was led by SR One with participation from Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures. As part of the financing, Simeon J. George, M.D., and Nilesh Kumar, Ph.D., joined Auxogyn's board of directors. The company is led by President and CEO Lissa Goldenstein. Auxogyn focuses on advancing women's reproductive health through its Early Embryo Viability Assessment (Eeva) system. Eeva is a non-invasive product whose proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division timing parameters to provide quantitative viability information. The company says Eeva's data can help IVF clinicians optimize treatment paths for patients undergoing IVF procedures. Auxogyn is privately held and has raised $20M in Series A financing from Kleiner Perkins Caufield & Byers, TPG Biotech and Merck Serono Ventures. Management expects to announce data from a five-site, 150-patient clinical study in the months ahead to support regulatory filings in Europe and the United States. The company executed an aggressive operating plan and anticipated commercializing Eeva in the latter half of 2012.

Total raised

$63M

Funding rounds

5

Latest round

Series B

Latest activity

May 2017